Responses
Clinical/translational cancer immunotherapy
Original research
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
Compose a Response to This Article
Other responses
No responses have been published for this article.
